These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 4531217)

  • 21. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections.
    Kozlowski DA; Connor B; Tillerson JL; Schallert T; Bohn MC
    Exp Neurol; 2000 Nov; 166(1):1-15. PubMed ID: 11031079
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exogenous l-DOPA induce no dopamine immuno-reactivity in striatal astroglias and microglias of adult rats with extensive nigro-striatal dopaminergic denervation.
    Maeda T; Nagata K; Yoshida Y
    Neurosci Lett; 2008 Mar; 433(3):255-8. PubMed ID: 18255227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 6-hydroxydopamine-induced degeneration of the nigrostriatal dopamine pathway: the turning syndrome.
    Ungerstedt U
    Pharmacol Ther B; 1976; 2(1):37-40. PubMed ID: 772721
    [No Abstract]   [Full Text] [Related]  

  • 24. Role of the nigrostriatal dopaminergic neurons in mediating the effect of exogenous L-dopa in Parkinson's disease.
    Melamed E
    Mt Sinai J Med; 1988 Jan; 55(1):35-42. PubMed ID: 3279303
    [No Abstract]   [Full Text] [Related]  

  • 25. Rats with unilateral median forebrain bundle, but not striatal or nigral, lesions by the neurotoxins MPP+ or rotenone display differential sensitivity to amphetamine and apomorphine.
    Sindhu KM; Banerjee R; Senthilkumar KS; Saravanan KS; Raju BC; Rao JM; Mohanakumar KP
    Pharmacol Biochem Behav; 2006 Jun; 84(2):321-9. PubMed ID: 16820197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Chronology of the extrapyramidal effects of neuroleptics, and the nigrostriatal dopaminergic system].
    Petit M; Lepine JP; Lesieur P
    Encephale; 1979; 5(4):297-316. PubMed ID: 42527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of 6-hydroxydopamine to create lesions in catecholamine neurons in rats.
    Mendez JS; Finn BW
    J Neurosurg; 1975 Feb; 42(2):166-73. PubMed ID: 234524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Degeneration of dopaminergic neurons and free radicals. Possible participation of levodopa.
    Ogawa N; Edamatsu R; Mizukawa K; Asanuma M; Kohno M; Mori A
    Adv Neurol; 1993; 60():242-50. PubMed ID: 8380518
    [No Abstract]   [Full Text] [Related]  

  • 29. Origin of various enzymes released from the substantia nigra and caudate nucleus: effects of 6-hydroxydopamine lesions of the nigro-striatal pathway.
    Greenfield SA; Grünewald RA; Foley P; Shaw SG
    J Comp Neurol; 1983 Feb; 214(1):87-92. PubMed ID: 6404955
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
    Fleming SM; Delville Y; Schallert T
    Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pharmacological and anatomical substrates of the amphetamine response in the rat.
    Creese I; Iversen SD
    Brain Res; 1975 Jan; 83(3):419-36. PubMed ID: 234270
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Specificity of the effect on the avoidance conditionning of microinjections of 6-hydroxydopamine in rat nigro-striatal system].
    Echavarria-Mage MT; Senault B; Delacour J
    C R Acad Hebd Seances Acad Sci D; 1976 Mar; 282(9):905-7. PubMed ID: 820478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reversal of behavioural abnormalities by fetal allografts in a novel rat model of striatonigral degeneration.
    Wenning GK; Granata R; Laboyrie PM; Quinn NP; Jenner P; Marsden CD
    Mov Disord; 1996 Sep; 11(5):522-32. PubMed ID: 8866493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Levodopa induction of Fos immunoreactivity in rat brain following partial and complete lesions of the substantia nigra.
    Cole DG; Growdon JH; DiFiglia M
    Exp Neurol; 1993 Apr; 120(2):223-32. PubMed ID: 8491280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats.
    Rojo AI; Cavada C; de Sagarra MR; Cuadrado A
    Exp Neurol; 2007 Nov; 208(1):120-6. PubMed ID: 17880941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dopamine transporter function assessed by antisense knockdown in the rat: protection from dopamine neurotoxicity.
    Van Kampen JM; McGeer EG; Stoessl AJ
    Synapse; 2000 Sep; 37(3):171-8. PubMed ID: 10881039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
    Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiparkinsonian drugs and dopaminergic neostriatal mechanisms: studies in rats with unilateral 6-hydroxydopamine (=6-OH-DA)-induced degeneration of the nigro-neostriatal DA pathway and quantitative recording of rotational behaviour.
    Fuxe K; Ungerstedt U
    Pharmacol Ther B; 1976; 2(1):41-7. PubMed ID: 817332
    [No Abstract]   [Full Text] [Related]  

  • 39. Partial selectivity of 6-OHDA induced neuronal degeneration after intraissular injection in the brain with special reference to the nigro-striatal dopamine system.
    Javoy F
    J Neural Transm; 1975; 37(3):219-27. PubMed ID: 1185167
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Tremor and motility following oxotremorine and harmine in rats with lesions of the nigro-striatal system].
    Westermann KH; Oelszner W; Staib AH; Funk K
    Acta Biol Med Ger; 1974; 33(1):67-76. PubMed ID: 4153886
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.